臨床外科76巻13号

2021年12月発行

特集 Conversion surgeryアップデート

がん種別の最新動向

局所進行直腸癌に対する術前治療戦略

著者： 植村守¹

所属機関： ¹大阪大学大学院医学系研究科消化器外科学

ページ範囲：P.1478 - P.1484

文献概要

【ポイント】
◆直腸癌治療の大原則は直腸間膜全切除（TME）であるが，治癒切除困難な局所進行直腸癌に対しては，術前治療が不可欠な要素となる．
◆高度局所進行直腸癌の多くが他臓器合併切除により根治的切除が可能となるが，個々の状況に応じて，安全な切除が難しい場合には，相対的切除不能例として有効な術前治療を組み合わせることが肝心である．

参考文献

1）Rawla P, Sunkara T, Barsouk A：Epidemiology of colorectal cancer：incidence, mortality, survival, and risk factors. Prz Gastroenterol 14：89-103, 2019

2）大腸癌研究会（編）：大腸癌治療ガイドライン　医師用　2019年版．金原出版2019

3）Uemura M, Ikeda M, Sekimoto M, et al：Prevention of Severe Pelvic Abscess Formation Following Extended Radical Surgery for Locally Recurrent Rectal Cancer. Ann Surg Oncol 16：2204-2210, 2009

4）植村　守，関本貢嗣，三宅正和，他：直腸癌局所再発に対する手術．手術72：649-657，2018

5）植村　守，関本貢嗣，三宅正和，他：直腸癌局所再発に対する集学的治療—術前放射線化学療法．外科78：1486-1492，2016

6）植村　守，朴　正勝，北風雅敏，他：仙骨合併切除を伴う直腸癌局所再発症例に対する術前治療．癌の臨床64：409-413，2018

7）Deng Y, Chi P, Lan P, et al：Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer：Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase Ⅲ Trial. J Clin Oncol 34：3300-3307, 2016

8）Heald RJ：A new approach to rectal cancer. Br J Hosp Med 22：277-281, 1979

9）Kapiteijn E, Marijnen CA, Nagtegaal ID, et al：Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345：638-646, 2001

10）Kusters M, Beets GL, van de Velde CJ, et al：A comparison between the treatment of low rectal cancer in Japan and the Netherlands, focusing on the patterns of local recurrence. Ann Surg 249：229-235, 2009

11）Glynne-Jones R, Wyrwicz L, Tiret E, et al：Rectal cancer：ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28（suppl_4）：iv22-iv40, 2017

12）Benson AB, Venook AP, Al-Hawary MM, et al：NCCN Guidelines Insights：Rectal Cancer, Version 6.2020. J Natl Compr Canc Netw 18：806-815, 2020

13）van Gijn W, Marijnen CA, Nagtegaal ID, et al：Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer：12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12：575-582, 2011

14）Sebag-Montefiore D, Stephens RJ, Steele R, et al：Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer（MRC CR07 and NCIC-CTG C016）：a multicentre, randomised trial. Lancet 373：811-820, 2009

15）Ngan SY, Burmeister B, Fisher RJ, et al：Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer：Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 30：3827-3833, 2012

16）Gerard JP, Azria D, Gourgou-Bourgade S, et al：Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 30：4558-4565, 2012

17）Aschele C, Cionini L, Lonardi S, et al：Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer：pathologic results of the STAR-01 randomized phase Ⅲ trial. J Clin Oncol 29：2773-2780, 2011

18）Bujko K, Wyrwicz L, Rutkowski A, et al：Long-course oxaliplatin-based preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer：results of a randomized phase Ⅲ study. Ann Oncol 27：834-842, 2016

19）Rodel C, Graeven U, Fietkau R, et al：Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer（the German CAO/ARO/AIO-04 study）：final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 16：979-989, 2015

20）O'Connell MJ, Colangelo LH, Beart RW, et al：Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer：surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 32：1927-1934, 2014

21）Allegra CJ, Yothers G, O'Connell MJ, et al：Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients：A Phase Ⅲ Randomized Clinical Trial. J Natl Cancer Inst 107：000-000, 2015

22）Petrelli F, Trevisan F, Cabiddu M, et al：Total Neoadjuvant Therapy in Rectal Cancer：A Systematic Review and Meta-analysis of Treatment Outcomes. Ann Surg 271：440-448, 2020

23）Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al：Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93：1215-1223, 2006

24）Pettersson D, Lorinc E, Holm T, et al：Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. Br J Surg 102：972-978；discussion 978, 2015

25）Probst CP, Becerra AZ, Aquina CT, et al：Extended Intervals after Neoadjuvant Therapy in Locally Advanced Rectal Cancer：The Key to Improved Tumor Response and Potential Organ Preservation. J Am Coll Surg 221：430-440, 2015

26）Prionas ND KA, Chang DT：Short-Course Vs Long-Course Radiotherapy：Pros and Cons. Current Common Dilemmas in Colorectal Surgery：Springer 2018：329-339.

27）Wang J, Long Y, Liu K, et al：Comparing neoadjuvant long-course chemoradiotherapy with short-course radiotherapy in rectal cancer. BMC Gastroenterol 21：277, 2021

28）Deng Y, Chi P, Lan P, et al：Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer：Final Results of the Chinese FOWARC Trial. J Clin Oncol 37：3223-3233, 2019

29）Schrag D, Weiser MR, Goodman KA, et al：Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer：a pilot trial. J Clin Oncol 32：513-518, 2014

30）Nishimura J, Hasegawa J, Kato T, et al：Phase Ⅱ trial of capecitabine plus oxaliplatin（CAPOX）as perioperative therapy for locally advanced rectal cancer. Cancer Chemother Pharmacol 82：707-716, 2018

31）Nishimura J, Hasegawa J, Noura S, et al：Adjuvant Chemotherapy after Neoadjuvant Chemotherapy and Long-term Outcomes of CAPOX Plus Bevacizumab Followed by TME for High-risk Localized Rectal Cancer. J Anus Rectum Colon 4：108-113, 2020

32）Hasegawa S, Goto S, Matsumoto T, et al：A Multicenter Phase 2 Study on the Feasibility and Efficacy of Neoadjuvant Chemotherapy Without Radiotherapy for Locally Advanced Rectal Cancer. Ann Surg Oncol 24：3587-3595, 2017

33）Manatakis DK, Gouvas N, Souglakos J, et al：Neo-adjuvant chemotherapy alone for the locally advanced rectal cancer：a systematic review. Int J Clin Oncol 25：1570-1580, 2020

34）Glynne-Jones R, Hava N, Goh V, et al：Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery（BACCHUS）：a phase Ⅱ, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum. BMC Cancer 15：764, 2015

35）Fernandez-Martos C, Garcia-Albeniz X, Pericay C, et al：Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery：long-term results of the Spanish GCR-3 phase Ⅱ randomized trialdagger. Ann Oncol 26：1722-1728, 2015

36）Cisel B, Pietrzak L, Michalski W, et al：Long-course preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer：long-term results of the randomized Polish Ⅱ study. Ann Oncol 30：1298-1303, 2019

37）Bosset JF, Calais G, Mineur L, et al：Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer：long-term results of the EORTC 22921 randomised study. Lancet Oncol 15：184-190, 2014

38）Cercek A, Roxburgh CSD, Strombom P, et al：Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncol 4：e180071, 2018

39）Bahadoer RR, Dijkstra EA, van Etten B, et al：Short-course radiotherapy followed by chemotherapy before total mesorectal excision（TME）versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer（RAPIDO）：a randomised, open-label, phase 3 trial. Lancet Oncol 22：29-42, 2021

40）Brouquet A, Bachet JB, Huguet F, et al：NORAD01-GRECCAR16 multicenter phase Ⅲ non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer（intergroup FRENCH-GRECCAR- PRODIGE trial）. BMC Cancer 20：485, 2020

41）Conroy T, Bosset JF, Etienne PL, et al：Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer（UNICANCER-PRODIGE 23）：a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22：702-715, 2021